68Ga-NOTA-PEG2-RM26 PET/CT, First in Man Study

Summary

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-PEG2-RM26 in prostate cancer patients. A single dose of 2 MBq/kg of 68Ga-NOTA-PEG2-RM26 limited to 100-200 MBq per examination will be given intravenously. Visual and semiquantitative method will be used to assess PET/CT images.

Timeline

Start

2022-06-01

Primary completion

2023-12-31

Completion

2023-12-31

Publications

• Bjareback A, Estenberg U, Tzortzakakis A, Axelsson R, Li C, Altena R, Tran TA, Hindorf C. First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer. EJNMMI Res. 2026 Jun 18;16(1):96. doi: 10.1186/s13550-026-01472-2.

Drugs

Indications